about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesEvolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous HistologiesAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsPhotodynamic nanomedicine in the treatment of solid tumors: perspectives and challengesBiosafe nanoscale pharmaceutical adjuvant materialsCo-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patientsAdding vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantlyClinical Translation of Nanomedicine.Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.Polymeric micelles in anticancer therapy: targeting, imaging and triggered release.Polymersomes: a new multi-functional tool for cancer diagnosis and therapy.Water-Soluble Derivatives of Octanuclear Iron-Oxo-Pyrazolato Complexes; An Experimental and Computational Study.Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism.Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs.Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.Presentation and management of docetaxel-related adverse effects in patients with breast cancerRandomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.Paclitaxel and trastuzumab for breast cancer.Drug delivery systems for intraperitoneal therapyManagement of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendationsTaxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patientsNanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel.Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment.Enhanced brain delivery of lamotrigine with Pluronic(®) P123-based nanocarrierDocetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.Prophylaxis for paclitaxel hypersensitivity reactions.Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif.Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)-paclitaxel nanoparticlesA novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety.Novel formulations of taxanes: a review. Old wine in a new bottle?Paclitaxel, Carboplatin, and trastuzumab.
P2860
Q24657308-513803ED-8203-453B-AF4E-1BB819047ECBQ26745420-0AF35D35-5CC2-4ADF-9E30-DA5336357AD8Q26766180-28912646-066E-462A-B0CB-3911B45A1EBFQ26766254-72B10DAF-7D91-4D11-A6E5-C9352830A2DDQ26798674-84C778CB-2035-4617-9FB9-698361926F0BQ26827820-5902C777-9ADD-406D-9B0A-F077A5B8891AQ26829798-1B0ED28E-1C46-4030-9E38-77A5D0BC4D71Q28345475-020826C1-EE20-477A-83F2-02CFA423667EQ28545246-3CA5D434-094E-48CF-9548-AF2922237BB4Q30355939-5749E376-EB27-4EB6-B7F0-154BEC39F7EEQ30465439-2C3CA964-355D-4E77-8E44-CC41733EA708Q30478123-22804C70-37D8-4CD0-BFEF-134217E8AB1DQ30488115-691A8C5E-EC8F-45EE-8DB1-A33D32AE9C4AQ30748546-B3B35081-F6B3-40D6-9830-AEA56F1935FFQ31402222-6269B138-57F8-4B97-B2EC-6AD8358DFF39Q33264052-52D18C0C-3A4B-44E6-82AA-46683BC8CABFQ33369720-CD21AEFA-5573-47D6-B8A8-C4DCBF88FCD7Q33412928-D20B8A8F-A6F0-4236-A33D-7113997B091DQ33437949-3853AD28-6533-4682-A02F-6E12DEA9C033Q33613579-1C8AE4A0-C2DF-4043-9378-E6F426EEC551Q33698286-D7A3208D-E23B-4EEF-A8A0-9036BAF2336CQ33738990-11DDE925-7779-4241-9DAC-92C8B57FF3C0Q33774695-BB93E80B-6E9F-405D-954A-3D9F87368742Q33774794-4E5B1D04-7409-41C3-A0BE-B5C58334CAFAQ33787894-65DA4C59-891E-45AE-96E4-FB946196CCF9Q33982751-ABE1A07E-F38B-4E22-8E24-BEEB719841CEQ34005121-5BC98AEF-2672-4B24-A0BE-36A4E5F072BBQ34005908-07DBDA8F-A7FB-4604-8425-61FFB3CC2FFEQ34011141-41AC8ACA-98D8-4306-8593-57E60B6A2F73Q34029697-99DC7F0D-910E-4271-B104-207BC7219772Q34075276-F61F9008-87CB-49B9-B665-8A882C34D478Q34093624-483BB4B9-93EB-4A3F-8AEF-488A84E24E7BQ34284213-8E5ED1EE-1A20-4603-AF14-831D01D0E003Q34344140-4495AB9C-6B00-4762-9829-B315FE85E685Q34382562-24FD1ECD-8B66-44D6-847D-A97B9EE78A39Q34497005-1E45596D-AB0E-4619-A4C4-79E8B9123847Q34513963-D1668A58-D0FC-4F81-82FA-3033A0D49011Q34557766-68183626-67B4-4802-B588-BFEC383E7720Q34563540-FE50BEB9-B517-4CAE-B776-13CE9B26FF2DQ34612916-AEAED044-1E83-494F-950A-756D457D8AD7
P2860
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Hypersensitivity reactions from taxol.
@en
Hypersensitivity reactions from taxol.
@nl
type
label
Hypersensitivity reactions from taxol.
@en
Hypersensitivity reactions from taxol.
@nl
prefLabel
Hypersensitivity reactions from taxol.
@en
Hypersensitivity reactions from taxol.
@nl
P2093
P1476
Hypersensitivity reactions from taxol.
@en
P2093
B Leyland-Jones
D A Van Echo
D D Von Hoff
P H Wiernik
R C Donehower
R J Gralla
P304
P356
10.1200/JCO.1990.8.7.1263
P407
P577
1990-07-01T00:00:00Z